Mismatch Repair Loss Renders ER+/HER2- Breast Cancer Susceptible to HER2/3 Inhibition

Abstract

The objective of this proposed study is to investigate a role for HER2/3 activation in MutLdefective ER+ breast cancer progression and resistance to endocrine therapy. By targeting HER2/3 signaling and key nodes of adaptive kinome response, we aim to significantly improve patient disease-specific survival.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Mar 01, 2020
Accession Number
AD1104156

Entities

People

  • Svasti Haricharan

Organizations

  • Sanford Burnham Prebys Medical Discovery Institute

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Cell Line
  • Cells
  • Chemical Compounds
  • Clinical Trials
  • Covid-19
  • Department Of Defense
  • Education
  • Electronic Mail
  • Growth Factors
  • Inhibition
  • Inhibitors
  • Maryland
  • Medical Personnel
  • Neoplasms
  • Patent Applications
  • Professional Development
  • Resistance
  • Targeting
  • Therapy
  • Training

Fields of Study

  • Medicine

Readers

  • Molecular and genetic basis of cancer.
  • Oncology